减肥巨头的争斗从未休止。8月31日，诺和诺德宣布了一项真实世界数据：在治疗过程中用药中断不超过30天的情况下，相比于替尔泊肽，司美格鲁肽在降低心脏病、卒中的发生，以及患者全因死亡风险降低了57%。无论中断与否，所有接受司美格鲁肽治疗的患者心脏病发作及相关死亡风险降低了29%。诺和诺德近期很不顺。在减重和降糖领域，礼来的替尔泊肽已经头对头试验中打败了司美格鲁肽，显现出全面的优越性。所以，诺和诺德这次...
Source Link减肥巨头的争斗从未休止。8月31日，诺和诺德宣布了一项真实世界数据：在治疗过程中用药中断不超过30天的情况下，相比于替尔泊肽，司美格鲁肽在降低心脏病、卒中的发生，以及患者全因死亡风险降低了57%。无论中断与否，所有接受司美格鲁肽治疗的患者心脏病发作及相关死亡风险降低了29%。诺和诺德近期很不顺。在减重和降糖领域，礼来的替尔泊肽已经头对头试验中打败了司美格鲁肽，显现出全面的优越性。所以，诺和诺德这次...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.